Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer

Oncotarget

Volumn 5, Issue 22, 2014, Pages 11054-11063

  Bria, Emilio ^a,b   Di Modugno, Francesca ^a   Sperduti, Isabella ^a   Iapicca, Pierluigi ^a   Visca, Paolo ^a   Alessandrini, Gabriele ^a   Antoniani, Barbara ^a   Pilotto, Sara ^b   Ludovini, Vienna ^c   Vannucci, Jacopo ^c   Bellezza, Guido ^c   Sidoni, Angelo ^c   Tortora, Giampaolo ^b   Radisky, Derek C ^d   Crinò, Lucio ^c   Cognetti, Francesco ^a   Facciolo, Francesco ^a   Mottolese, Marcella ^a   Milella, Michele ^a   Nisticò, Paola ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d MAYO CLINIC   (United States)

Author keywords

Biomarkers; Lung cancer; Splicing

Indexed keywords

ACTIN CYTOSKELETON REGULATOR HUMAN MENA; ACTIN CYTOSKELETON REGULATOR HUMAN MENA 11A; ACTIN CYTOSKELETON REGULATOR HUMAN MENA DELTA V6; REGULATOR PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; ACTIN BINDING PROTEIN; ENAH PROTEIN, HUMAN; ISOPROTEIN;

A549 CELL LINE; ALTERNATIVE RNA SPLICING; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EARLY CANCER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; TUMOR INVASION; TUMOR VOLUME; VALIDATION PROCESS; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; GENETICS; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; TUMOR CELL LINE; TUMOR RECURRENCE;

ALTERNATIVE SPLICING; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; MICROFILAMENT PROTEINS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTEIN ISOFORMS; RISK ASSESSMENT;

EID: 84917738647     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2609     Document Type: Article

References (33)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians. 2013; 63(1):11-30.
2. Walters S, Maringe C, Coleman MP, Peake MD, Butler J, Young N, Bergstrom S, Hanna L, Jakobsen E, Kolbeck K, Sundstrom S, Engholm G, Gavin A, Gjerstorff ML, Hatcher J, Johannesen TB, et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007. Thorax. 2013; 68(6):551-564.
3. Wender R, Fontham ET, Barrera E, Jr., Colditz GA, Church TR, Ettinger DS, Etzioni R, Flowers CR, Gazelle GS, Kelsey DK, LaMonte SJ, Michaelson JS, Oeffinger KC, Shih YC, Sullivan DC, Travis W, et al. American Cancer Society lung cancer screening guidelines. CA: a cancer journal for clinicians. 2013; 63(2):107-117.
4. Group NM-aC, Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, Le Chevalier T, Le Pechoux C, Parmar MK, Pignon JP, Souhami RL, Stephens RJ, Stewart LA, Tierney JF, Tribodet H and van Meerbeeck J. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010; 375(9722):1267-1277.
5. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006; 355(10):983-991.
6. Tsao MS, Aviel-Ronen S, Ding K, Lau D, Liu N, Sakurada A, Whitehead M, Zhu CQ, Livingston R, Johnson DH, Rigas J, Seymour L, Winton T and Shepherd FA. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol. 2007; 25(33):5240-5247.
7. Dienstmann R, Martinez P and Felip E. Personalizing therapy with targeted agents in non-small cell lung cancer. Oncotarget. 2011; 2(3):165-177.
8. Wright GM, Do H, Weiss J, Alam NZ, Rathi V, Walkiewicz M, John T, Russell PA and Dobrovic A. Mapping of actionable mutations to histological subtype domains in lung adenocarcinoma: implications for precision medicine. Oncotarget. 2014; 5(8):2107-2115.
9. Fawdar S, Edwards ZC and Brognard J. Druggable drivers of lung cancer. Oncotarget. 2013; 4(9):1334-1335.
10. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, Cheng CL, Wang CH, Terng HJ, Kao SF, Chan WK, Li HN, Liu CC, Singh S, Chen WJ, Chen JJ, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med. 2007; 356(1):11-20.
11. Wistuba, II, Behrens C, Lombardi F, Wagner S, Fujimoto J, Raso MG, Spaggiari L, Galetta D, Riley R, Hughes E, Reid J, Sangale Z, Swisher SG, Kalhor N, Moran CA, Gutin A, et al. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma. Clin Cancer Res. 2013; 19(22):6261-6271.
12. Pajares MJ, Ezponda T, Catena R, Calvo A, Pio R and Montuenga LM. Alternative splicing: an emerging topic in molecular and clinical oncology. The Lancet Oncology. 2007; 8(4):349-357.
13. Gertler FB, Niebuhr K, Reinhard M, Wehland J, Soriano P. Mena, a relative of VASP and Drosophila Enabled, is implicated in the control of microfilament dynamics. Cell. 1996; 87(2):227-239.
14. Di Modugno F, Iapicca P, Boudreau A, Mottolese M, Terrenato I, Perracchio L, Carstens RP, Santoni A, Bissell MJ and Nistico P. Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(47):19280-19285.
15. Warzecha CC, Sato TK, Nabet B, Hogenesch JB and Carstens RP. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell. 2009; 33(5):591-601.
16. Di Modugno F, DeMonte L, Balsamo M, Bronzi G, Nicotra MR, Alessio M, Jager E, Condeelis JS, Santoni A, Natali PG and Nistico P. Molecular cloning of hMena (ENAH) and its splice variant hMena+11a: epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines. Cancer Res. 2007; 67(6):2657-2665.
17. Pino MS, Balsamo M, Di Modugno F, Mottolese M, Alessio M, Melucci E, Milella M, McConkey DJ, Philippar U, Gertler FB, Natali PG and Nistico P. Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines. Clin Cancer Res. 2008; 14(15):4943-4950.
18. Petersen OW, Ronnov-Jessen L, Howlett AR and Bissell MJ. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proceedings of the National Academy of Sciences of the United States of America. 1992; 89(19):9064-9068.
19. Liu J, Lee W, Jiang Z, Chen Z, Jhunjhunwala S, Haverty PM, Gnad F, Guan Y, Gilbert HN, Stinson J, Klijn C, Guillory J, Bhatt D, Vartanian S, Walter K, Chan J, et al. Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Res. 2012; 22(12):2315-2327.
20. Di Modugno F, Mottolese M, DeMonte L, Trono P, Balsamo M, Conidi A, Melucci E, Terrenato I, Belleudi F, Torrisi MR, Alessio M, Santoni A and Nistico P. The cooperation between hMena overexpression and HER2 signalling in breast cancer. PLoS One. 2010; 5(12):e15852.
21. Agarwal S, Gertler FB, Balsamo M, Condeelis JS, Camp RL, Xue X, Lin J, Rohan TE and Rimm DL. Quantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer. Breast Cancer Res. 2012; 14(5):R124.
22. Iasonos A, Schrag D, Raj GV and Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008; 26(8):1364-1370.
23. Bria E, Milella M, Sperduti I, Alessandrini G, Visca P, Corzani F, Giannarelli D, Cerasoli V, Cuppone F, Cecere FL, Marchetti A, Sacco R, Mucilli F, Malatesta S, Guetti L, Vitale L, et al. A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer. Lung Cancer. 2009; 66(3):365-371.
24. Chen DT, Hsu YL, Fulp WJ, Coppola D, Haura EB, Yeatman TJ and Cress WD. Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer. J Natl Cancer Inst. 2011; 103(24):1859-1870.
25. Kratz JR, He J, Van Den Eeden SK, Zhu ZH, Gao W, Pham PT, Mulvihill MS, Ziaei F, Zhang H, Su B, Zhi X, Quesenberry CP, Habel LA, Deng Q, Wang Z, Zhou J, et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet. 2012; 379(9818):823-832.
26. Shuster JJ. Median follow-up in clinical trials. J Clin Oncol. 1991; 9(1):191-192.
27. Milella M, Nuzzo C, Bria E, Sperduti I, Visca P, Buttitta F, Antoniani B, Merola R, Gelibter A, Cuppone F, D'Alicandro V, Ceribelli A, Rinaldi M, Cianciulli A, Felicioni L, Malatesta S, et al. EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy. J Thorac Oncol. 2012; 7(4):672-680.
28. Pintilie M, Iakovlev V, Fyles A, Hedley D, Milosevic M and Hill RP. Heterogeneity and power in clinical biomarker studies. J Clin Oncol. 2009; 27(9):1517-1521.
29. Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med. 1995; 14(15):1707-1723.
30. Sauerbrei W and Schumacher M. A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med. 1992; 11(16):2093-2109.
31. Lemeshow S and Le Gall JR. Modeling the severity of illness of ICU patients. A systems update. Jama. 1994; 272(13):1049-1055.
32. Measures to assess the prognostic ability of the stratified Cox proportional hazards model. Stat Med. 2009; 28(3):389-411.
33. Kaplan EL and Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53:457-481.